Skip to content

IL-7 may boost CD4 and CD8 T-cells, study shows

Genetic test predicts who will respond to hepatitis C treatment

Triple-drug treatment during pregnancy reduces risk of nevirapine resistance

Abacavir as potent as tenofovir for patients starting HIV treatment with a high viral load

Raltegravir moves closer to approval for first-line use in Europe

Experimental integrase inhibitor GSK-572 looks good in early studies

Once-daily Kaletra as safe and effective as twice-daily dosing

TB Alliance, Tibotec, form partnership to take forward new drug

New hepatitis C drug may halve the length of treatment, but ribavirin still needed